Igor Klyubin

Igor Klyubin

Auto-generated profile, based on publicly available information

Igor Klyubin

Department of Pharmacology and Therapeutics, School of Medicine, and Institute of Neuroscience, Trinity College, Dublin 2, Ireland

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2013 in Molecular Brain
Verified
Journal Article
Open access
PDF file
KAKyongman An
Kyongman An
IKIgor Klyubin
Igor Klyubin
YKYoungkyu Kim
Youngkyu Kim
JJJung Hoon Jung
Jung Hoon Jung
AMAlexandra J Mably
Alexandra J Mably
JKJoung-Hun Kim
Joung-Hun Kim
Exosomes, small extracellular vesicles of endosomal origin, have been suggested to be involved in both the metabolism and aggregation of Alzheimer’s disease (AD)-associated amyloid β-protein (Aβ). Despite their ubiquitous presence and the inclusion of components which can potentially interact with Aβ, the role of exosomes in regulating synaptic dysfunction induced by Aβ has not been explored. We here provide in vivo evidence that exosomes derived from N2a cells or human cerebrospinal fluid can abrogate the synaptic-plasticity-disrupting activity of both synthetic and AD brain-derived Aβ. Mechanistically, this effect involves sequestration of synaptotoxic Aβ assemblies by exosomal surface proteins such as PrPC rather than Aβ proteolysis. These data suggest that exosomes can counteract the inhibitory action of Aβ, which contributes to perpetual capability for synaptic plasticity.

1 January 2012 in Molecular Brain
Verified
Journal Article
Open access
PDF file
IKIgor Klyubin
Igor Klyubin
WCWilliam K Cullen
William K Cullen
NHNengwei Hu
Nengwei Hu
MRMichael Rowan
Michael Rowan
Alzheimer’s disease (AD) is characterized by episodic memory impairment that often precedes clinical diagnosis by many years. Probing the mechanisms of such impairment may provide much needed means of diagnosis and therapeutic intervention at an early, pre-dementia, stage. Prior to the onset of significant neurodegeneration, the structural and functional integrity of synapses in mnemonic circuitry is severely compromised in the presence of amyloidosis. This review examines recent evidence evaluating the role of amyloid-ß protein (Aβ) in causing rapid disruption of synaptic plasticity and memory impairment. We evaluate the relative importance of different sizes and conformations of Aβ, including monomer, oligomer, protofibril and fibril. We pay particular attention to recent controversies over the relevance to the pathophysiology of AD of different water soluble Aβ aggregates and the importance of cellular prion protein in mediating their effects. Current data are consistent with the view that both low-n oligomers and larger soluble assemblies present in AD brain, some of them via a direct interaction with cellular prion protein, cause synaptic memory failure. At the two extremes of aggregation, monomers and fibrils appear to act in vivo both as sources and sinks of certain metastable conformations of soluble aggregates that powerfully disrupt synaptic plasticity. The same principle appears to apply to other synaptotoxic amyloidogenic proteins including tau, α-synuclein and prion protein.

1 June 2018 in Neurobiology of Disease
Verified
Journal Article
Closed access
YQYingjie Qi
Yingjie Qi
IKIgor Klyubin
Igor Klyubin
ACA Claudio Cuello
A Claudio Cuello
MRMichael Rowan
Michael Rowan

24 December 2014 in Acta Neuropathologica Communications
Verified
Journal Article
Open access
PDF file
YQYingjie Qi
Yingjie Qi
IKIgor Klyubin
Igor Klyubin
SHSarah C Harney
Sarah C Harney
NHNengwei Hu
Nengwei Hu
WCWilliam K Cullen
William K Cullen
MRMichael Rowan
Michael Rowan
Long before synaptic loss occurs in Alzheimer’s disease significant harbingers of disease may be detected at the functional level. Here we examined if synaptic long-term potentiation is selectively disrupted prior to extracellular deposition of Aß in a very complete model of Alzheimer’s disease amyloidosis, the McGill-R-Thy1-APP transgenic rat. Longitudinal studies in freely behaving animals revealed an age-dependent, relatively rapid-onset and persistent inhibition of long-term potentiation without a change in baseline synaptic transmission in the CA1 area of the hippocampus. Thus the ability of a standard 200 Hz conditioning protocol to induce significant NMDA receptor-dependent short- and long-term potentiation was lost at about 3.5 months of age and this deficit persisted for at least another 2–3 months, when plaques start to appear. Consistent with in vitro evidence for a causal role of a selective reduction in NMDA receptor-mediated synaptic currents, the deficit in synaptic plasticity in vivo was associated with a reduction in the synaptic burst response to the conditioning stimulation and was overcome using stronger 400 Hz stimulation. Moreover, intracerebroventricular treatment for 3 days with an N-terminally directed monoclonal anti- human Aß antibody, McSA1, transiently reversed the impairment of synaptic plasticity. Similar brief treatment with the BACE1 inhibitor LY2886721 or the γ-secretase inhibitor MRK-560 was found to have a comparable short-lived ameliorative effect when tracked in individual rats. These findings provide strong evidence that endogenously generated human Aß selectively disrupts the induction of long-term potentiation in a manner that enables potential therapeutic options to be assessed longitudinally at the pre-plaque stage of Alzheimer’s disease amyloidosis.

1 July 2017 in Neuropharmacology
Verified
Journal Article
Open access
DZDainan Zhang
Dainan Zhang
YQYingjie Qi
Yingjie Qi
IKIgor Klyubin
Igor Klyubin
TOTomas Ondrejcak
Tomas Ondrejcak
CSClaire J. Sarell
Claire J. Sarell
MRMichael Rowan
Michael Rowan
Alzheimer's disease amyloid-β (Aβ) oligomers are synaptotoxic, inappropriately increasing extracellular glutamate concentration and glutamate receptor activation to thereby rapidly disrupt synaptic plasticity. Thus, acutely promoting brain glutamate homeostasis with a blood-based scavenging system, glutamate-oxaloacetate transaminase (GOT), and blocking metabotropic glutamate 5 (mGlu5) receptor or its co-receptor cellular prion protein (PrP), prevent the acute inhibition of long-term potentiation (LTP) by exogenous Aβ. Here, we evaluated the time course of the effects of such interventions in the persistent disruptive effects of Aβ oligomers, either exogenously injected in wild type rats or endogenously generated in transgenic rats that model Alzheimer's disease amyloidosis. We report that repeated, but not acute, systemic administration of recombinant GOT type 1, with or without the glutamate co-substrate oxaloacetate, reversed the persistent deleterious effect of exogenous Aβ on synaptic plasticity. Moreover, similar repetitive treatment reversibly abrogated the inhibition of LTP monitored longitudinally in freely behaving transgenic rats. Remarkably, brief repeated treatment with an mGlu5 receptor antagonist, basimglurant, or an antibody that prevents Aβ oligomer binding to PrP, ICSM35, also had similar reversible ameliorative effects in the transgenic rat model. Overall, the present findings support the ongoing development of therapeutics for early Alzheimer's disease based on these complementary approaches.

1 September 2023 in European Journal of Neuroscience
Verified
Journal Article
Open access
YYYin Yang
Yin Yang
TOTomas Ondrejcak
Tomas Ondrejcak
NHNeng‐Wei Hu
Neng‐Wei Hu
SISadia Islam
Sadia Islam
EOEugene O'ROurke
Eugene O'ROurke
IKIgor Klyubin
Igor Klyubin
Non‐invasive sensory stimulation in the range of the brain's gamma rhythm (30–100 Hz) is emerging as a new potential therapeutic strategy for the treatment of Alzheimer's disease (AD). Here, we investigated the effect of repeated combined exposure to 40 Hz synchronized sound and light stimuli on hippocampal long‐term potentiation (LTP) in vivo in three rat models of early AD. We employed a very complete model of AD amyloidosis, amyloid precursor protein (APP)‐overexpressing transgenic McGill‐R‐Thy1‐APP rats at an early pre‐plaque stage, systemic treatment of transgenic APP rats with corticosterone modelling certain environmental AD risk factors and, importantly, intracerebral injection of highly disease‐relevant AD patient‐derived synaptotoxic beta‐amyloid and tau in wild‐type animals. We found that daily treatment with 40 Hz sensory stimulation for 2 weeks fully abrogated the inhibition of LTP in all three models. Moreover, there was a negative correlation between the magnitude of LTP and the level of active caspase‐1 in the hippocampus of transgenic APP animals, which suggests that the beneficial effect of 40 Hz stimulation was dependent on modulation of pro‐inflammatory mechanisms. Our findings support ongoing clinical trials of gamma‐patterned sensory stimulation in early AD.